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        The convergence of human immunodeficiency virus (HIV) 
and tuberculosis (TB) epidemics in southern Africa has con-
tributed to a significant increase in reported cases of extrapul-
monary TB (EPTB).  1   One of the most common presentations 
of disease is pericardial TB, which in HIV co-infection is asso-
ciated with significant mortality and morbidity.  2   Cardiac tam-
ponade is a common and life-threatening complication of TB 
pericarditis that requires immediate medical intervention. 
  We report a case of TB pericarditis associated with HIV 
infection and its management in Hlabisa Hospital, a rural 
district hospital in northern KwaZulu-Natal, South Africa. 
Hlabisa is located at the epicenter of the intertwined HIV and 
TB epidemics: the prevalence of HIV is 21.5% in the adult 
population (15–49 years of age); the TB notification rate was 
1,700 per 100,000 persons in 2008; and the HIV co-infection 
rate for TB patients is 76%.  3   We discuss the identification and 
management of this condition in HIV-infected persons, with 
a focus on settings with limited resources for diagnosis and 
intervention. We highlight some of the key areas where further 
evidence is required to inform clinical practice. 
  CASE  REPORT 
  A 34-year old HIV-infected man (CD4 cell count = 310 
cells/mm  3  ) came to our hospital with a short history of increas-
ing dyspnea and dizziness. He reported chest pain, weight 
loss, night sweats, but no cough. On initial assessment, he 
was unwell, diaphoretic, tachycardic (heart rate = 128/min), 
hypotensive (blood pressure = 100/60 mm of Hg), and severely 
tachypnoeic (respiratory rate = 40/min). Jugular venous pres-
sure was increased. Chest radiograph demonstrated enlarged 
cardiac shadow. Because echocardiography was available 
on site, ultrasound was performed using a conventional 
B-Mode ultrasound scanner (Just Vision 400; Toshiba, Tokyo, 
Japan) with a 3.5-MHz abdominal probe and a sub-xiphoidal 
approach. A 3–4 cm pericardial effusion was seen, with 
impaired filling of the right ventricle and right atrium, the char-
acteristic sonographic signs of cardiac tamponade (  Figure 1   
and   Supplementary Video  1 ).  
  The patient was transferred to the high care unit for pericar-
diocentesis and continuous electrocardiography (ECG) moni-
toring. No dedicated pericardiocentesis set or central venous 
cannula was available at that time. Localization for intercos-
tal puncture approximately in the mid-clavicular line was 
determined by using ultrasound, and a 16-gauge intravenous 
cannula was inserted in the lower portion of the intercostal 
space. The needle was removed and 400 mL of clear yellow 
fluid was drained before removal. Despite the persistence of 
a large effusion, cardiac function improved significantly, and 
the clinical status improved significantly within thirty min-
utes (  Figure 2   and   Supplementary Video 2  ). Anti-tuberculous 
therapy (Rifafour  ®  ; Sanofi-Aventis, Midrand, South Africa, 
four tablets/day, a fixed-dose combination of rifampicin, iso-
niazid, ethambutol, and pyrazinamide)) and treatment with 
prednisolone (80 mg/day) were commenced. After two days, 
the condition had stabilized and the patient requested dis-
charge; at this time the effusion measured 1–2 cm (  Figure 3  ). 
Prednisolone was prescribed for one month and continued TB 
therapy was supervised at the primary health care clinic. After 
two months, antiretroviral therapy (stavudine/lamivudine/
efavirenz) was initiated. The six-month course of antituber-
culous therapy was completed uneventfully with no evidence 
of immune reconstitution inflammatory syndrome and ultra-
sound at the end of treatment demonstrated no residual peri-
cardial effusion. 
     DISCUSSION 
  Clinical manifestations of pericarditis (chest pain, cough, 
dyspnea) overlap with other disease entities in HIV-infected 
persons: most importantly pulmonary and pleural TB, but also 
bacterial pneumonia and   Pneumocystis jiroveci   pneumonia. 
Systemic signs (weight loss, night sweats, fatigue) may be pres-
ent but are non-discriminatory. Signs of heart failure may result 
from progression of pericardial effusion but HIV-infected per-
sons are also more likely to have myocardial involvement and 
hemodynamic instability.  4  
  A high index of suspicion for pericardial disease is therefore 
required in symptomatic HIV-infected persons, and it is impor-
tant that imaging is included in algorithms for smear-negative 
and extrapulmonary TB.  5   Although expansion of radiographic 
facilities would be welcomed, we would also like to see more 
extensive use of ultrasound techniques. Although cardiomeg-
aly observed by chest radiograph is suggestive of pericardial 
effusion, distinction from dilated cardiomyopathy requires 
ultrasound and formal echocardiography is rarely available in 
the district hospital setting. Recognition of the anechoic effu-
sion is normally straightforward; thickened pericardium with 
echogenic, exudative coating and fibrin strands may be seen 
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and increases the likelihood of tuberculous etiology.  6   If exper-
tise is available, it is also important to assess the right ventricu-
lar cavity because in cases of tamponade the diameter will be 
reduced and there might be a paradoxical inward motion or 
even collapse of the free wall. 
  Preliminary work from our group suggests that non-special-
ist physicians can be trained to identify key features of EPTB 
by using ultrasound.  7  However, pericardial effusion was a com-
mon finding in HIV-infected patients in this study and further 
research is required to establish clinical decision–making tools 
based on clinical features and sonographic appearance. 
  In countries with a high prevalence of TB, this disease has 
been reported as the cause of more than 90% of large peri-
cardial effusions in HIV-infected persons.  8   Other poten-
tial causes include bacterial pericarditis (e.g., non-typhoidal 
  Salmonella  ), human herpesvirus-8–related disease, and lym-
phoma. Definitive diagnosis of tuberculous etiology is chal-
lenging because studies have shown the yield from direct 
smear examination of pericardial fluid to be as low as 2%  9 ; 
culture of pericardial fluid is positive in 38–56% of cases.  9,  10  
Other indirect methods used to support TB diagnosis, such as 
adenosine deaminase levels in pericardial fluid, have the limi-
tation of lower sensitivity in persons with advanced HIV infec-
tion.  11   All diagnostic studies have the common problem of the 
lack of a definitive gold standard. Whether novel diagnostic 
technologies that use the polymerase chain reaction have suf-
ficient accuracy with samples such as pericardial fluid requires 
well-designed studies. 
  In the absence of sufficiently rapid, accurate diagnostic 
techniques, it is appropriate in high prevalence areas to initi-
ate empiric antituberculous therapy in the presence of large 
pericardial effusion. Diagnostic pericardial aspiration should 
be reserved for cases where there is evidence for an alterna-
tive diagnosis (e.g., skin lesions of Kaposi’s sarcoma) or suspi-
cion of drug-resistant TB. 
  Pericardiocentesis is often a life-saving intervention and is 
essential in patients with cardiac tamponade. In clinical stud-
ies, the proportion of patients with tamponade has ranged 
between 20% and 90% depending on the selection of patients 
and definition of tamponade.  4,  12   Cardiac tamponade is clas-
sically a clinical diagnosis characterized by increased jugular 
venous pressure, hypotension, and diminished heart sounds 
but cardiac ultrasound may identify typical features such as 
collapse of the right ventricle or right atrium. 
  According to standard protocols, a needle attached to the 
V  1   lead of an electrocardiograph machine is inserted into the 
pericardial space, commonly by a sub-xiphoidal approach. 
Echocardiographic control is recommended but the expertise 
is unlikely to be available in many settings. In settings where 
dedicated pericardiocentesis equipment is not available, the 
use of alternative approaches, such as intercostal approach 
with a simple cannula as described in our case, might be nec-
essary but should be guided by ultrasound (  Figure 4  ). It is 
necessary to drain only enough fluid to relieve the signs of 
hemodynamic instability. Many patients experience rapid clin-
ical improvement despite the continuing presence of pericar-
dial effusion. It is worth remembering that the aim is reduction 
of pressure in the pericardial space not volume   per se   and the 
drainage of 50–100 mL of fluid might suffice for resolution of 
tamponade. 
    Antituberculous therapy should be commenced as soon as 
a diagnosis of pericarditis is made in a setting with high preva-
lence of TB and HIV infection. Treatment regimens recom-
mended for pericardial TB are the same as for pulmonary TB, 
consisting of rifampicin, isoniazid, ethambutol, and pyrazin-
amide for two months, followed by rifampicin and isoniazid 
 F igure   1.        Ultrasound at presentation for the patient, showing 
large pericardial effusion and right ventricular collapse.       
 F igure   2.       Ultrasound post-pericardiocentesis for the patient, 
showing persistent large effusion but improved right ventricular filling.     
 F igure   3.        Ultrasound on day 3 for the patient, showing reduction 
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for four months.  13   The paucity of data informing the treatment 
of TB/HIV co-infection has recently been highlighted, with 
particular uncertainty for duration of therapy.  14   This is partic-
ularly striking for EPTB and it is crucial that common forms 
of EPTB are adequately represented in future trials of antitu-
berculous therapy. 
 Corticosteroids are frequently prescribed for TB pericarditis 
but the evidence to support their use in HIV-infected patients 
is limited. Studies conducted in the pre-HIV era suggested 
significant reduction in mortality with steroids in pericardial 
effusion and constrictive pericarditis.  15,  16   However, HIV infec-
tion influences the pathologic process and evidence suggests 
that constrictive pericarditis is much less common. The only 
randomized trial in HIV-infected patients included only 58 
patients and showed a non-significant trend to lower mortal-
ity with adjunctive steroids.  10   A Cochrane review on this topic 
concluded that prednisolone has no proven beneficial effect 
in patients with TB pericarditis.  17   An ongoing multicentre ran-
domized trial aims to address this key question.  18  
  It is important to remember that because rifampicin 
increases corticosteroid metabolism through hepatic enzyme 
induction, higher doses might be required.  19   Prednisolone 
doses as high as 120 mg have been used successfully in treat-
ing patients with TB pericarditis.  20  
  Pericardial TB is a World Health Organization stage IV 
condition and thus antiretroviral therapy is indicated regard-
less of CD4+ lymphocyte count.  21   There is recent evidence to 
support the early initiation of combination antiretroviral ther-
apy (ART) during antituberculous therapy for pulmonary TB, 
although the optimal time to start has yet to be determined.  22  
Patients with EPTB were not included in this trial and only 
observational data including patients with EPTB support the 
benefit of early antiretroviral therapy in this context.  23  
  The potential risks of early ART initiation include drug toxic-
ity, drug interactions, and immune reconstitution inflammatory 
syndrome. The occurrence of pericardial TB–immune reconstitu-
tion inflammatory syndrome has been reported but the morbid-
ity or mortality associated with this is unknown.  24   Theoretically, 
immune reconstitution could lead to re-accumulation of fluid 
(with the possibility of tamponade) and/or a higher risk of con-
strictive pericarditis. Our practice is to initiate ART after 2–8 
weeks of TB treatment and, as far as possible, to monitor the 
clinical status closely. 
   CONCLUSIONS 
 Pericardial TB is a frequent manifestation of HIV-associated 
TB and is associated with considerable mortality and morbid-
ity. Many questions remain in terms of optimal diagnosis and 
therapy for this condition. As we progress into a new era of 
TB diagnostics and therapeutics to address this public health 
emergency, it is imperative that clinical trials include patients 
with extrapulmonary TB to answer some of the questions 
highlighted here. 
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